Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
102.3 USD | -0.06% |
|
-.--% | -5.72% |
Jul. 01 | New semester, new state of mind | ![]() |
Jun. 26 | Redburn Atlantic Initiates Arkema at Buy | MT |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.21 for the current year.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.84 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.72% | 6.54B | - | ||
+2.08% | 101B | A- | ||
-10.18% | 59.19B | A- | ||
+82.86% | 50.62B | B | ||
+4.83% | 33.55B | B | ||
-1.02% | 30.23B | A- | ||
+3.77% | 18.17B | B- | ||
+20.79% | 17.33B | C+ | ||
+82.12% | 13.4B | B- | ||
+7.97% | 13.31B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AKE Stock
- ARKAF Stock
- Ratings Arkema